Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CSF2 [6] Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Shigellosis, Transcriptional misregulation in cancer, Rheumatoid arthritis D11343 Otilimab [2] 46, 256
2 FYN [9] Sphingolipid signaling pathway, Phospholipase D signaling pathway, Osteoclast differentiation, Platelet activation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Prion disease, Pathogenic Escherichia coli infection, Viral myocarditis D03658 Dasatinib [2] 51, 85
3 FYN [9] Sphingolipid signaling pathway, Phospholipase D signaling pathway, Osteoclast differentiation, Platelet activation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Prion disease, Pathogenic Escherichia coli infection, Viral myocarditis D06414 Dasatinib [2] 51, 85
4 HLA-A [5] Phagosome, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
5 HLA-B [5] Phagosome, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
6 HLA-C [5] Phagosome, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
7 HLA-E [5] Phagosome, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
8 HLA-G [5] Phagosome, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis D04318 Glatiramer [4] 2, 13, 96, 156
9 IFNA1 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
10 IFNA1 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
11 IFNA2 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
12 IFNA2 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
13 IFNA4 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
14 IFNA4 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
15 IFNA5 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
16 IFNA5 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
17 IFNA6 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
18 IFNA6 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
19 IFNA7 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
20 IFNA7 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
21 IFNA8 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
22 IFNA8 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
23 IFNA10 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
24 IFNA10 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
25 IFNA13 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
26 IFNA13 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
27 IFNA14 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
28 IFNA14 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
29 IFNA16 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
30 IFNA16 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
31 IFNA17 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
32 IFNA17 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
33 IFNA21 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09662 Rontalizumab [1] 49
34 IFNA21 [8] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer D09668 Sifalimumab [1] 49
35 IFNAR1 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D00745 Interferon alfa-2a [1] 56
36 IFNAR1 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D00746 Interferon beta-1b [1] 13
37 IFNAR1 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
38 IFNAR1 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
39 IFNAR1 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
40 IFNAR1 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
41 IFNAR1 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D11082 Anifrolumab [2] 46, 49
42 IFNAR2 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D00745 Interferon alfa-2a [1] 56
43 IFNAR2 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D00746 Interferon beta-1b [1] 13
44 IFNAR2 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
45 IFNAR2 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
46 IFNAR2 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
47 IFNAR2 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
48 IFNAR2 [7] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer D11082 Anifrolumab [2] 46, 49
49 IFNG [15] Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04242 Fontolizumab [1] 46
50 IFNG [15] Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D11120 Emapalumab [2] 49, 107
51 IFNGR1 [9] Necroptosis, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
52 IFNGR2 [9] Necroptosis, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
53 ITGAL [7] Rap1 signaling pathway, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Rheumatoid arthritis, Viral myocarditis D03959 Efalizumab [9] 11, 13, 37, 46, 49, 53, 61, 95, 96
54 LCK [9] NF-kappa B signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D03658 Dasatinib [2] 51, 85
55 LCK [9] NF-kappa B signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D06414 Dasatinib [2] 51, 85
56 PIK3CA [39] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
57 PIK3CB [39] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
58 PIK3CD [39] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
59 PIK3CD [39] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11437 Parsaclisib [3] 35, 53, 61
60 PPP3CA [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
61 PPP3CA [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
62 PPP3CA [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
63 PPP3CA [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
64 PPP3CA [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [1] 222
65 PPP3CB [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
66 PPP3CB [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
67 PPP3CB [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
68 PPP3CB [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
69 PPP3CB [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [1] 222
70 PPP3CC [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
71 PPP3CC [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
72 PPP3CC [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
73 PPP3CC [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
74 PPP3CC [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [1] 222
75 PPP3R1 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
76 PPP3R1 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
77 PPP3R1 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
78 PPP3R1 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
79 PPP3R1 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [1] 222
80 PPP3R2 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
81 PPP3R2 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
82 PPP3R2 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
83 PPP3R2 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
84 PPP3R2 [14] Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [1] 222
85 MAP2K1 [35] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib [1] 34
86 MAP2K1 [35] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
87 MAP2K1 [35] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib [1] 280
88 MAP2K1 [35] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib [1] 34
89 MAP2K2 [28] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib [1] 34
90 MAP2K2 [28] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
91 MAP2K2 [28] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib [1] 280
92 MAP2K2 [28] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib [1] 34
93 RAF1 [30] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D06272 Sorafenib [2] 34, 86
94 RAF1 [30] Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08524 Sorafenib [2] 34, 86
95 BRAF [16] Rap1 signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer D06272 Sorafenib [2] 34, 86
96 BRAF [16] Rap1 signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer D08524 Sorafenib [2] 34, 86
97 BRAF [16] Rap1 signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer D10064 Dabrafenib [1] 34
98 SYK [9] NF-kappa B signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Platelet activation, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Tuberculosis, Viral carcinogenesis D09347 Fostamatinib [4] 46, 49, 61, 66
99 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00742 Etanercept [17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
100 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
101 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
102 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02597 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
103 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02598 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
104 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D03441 Certolizumab pegol [8] 37, 46, 49, 96, 97, 107, 226, 271
105 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04358 Golimumab [8] 46, 56, 84, 96, 97, 107, 270, 271
106 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04687 Lenalidomide [8] 16, 26, 28, 34, 49, 284, 300, 331
107 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D05393 Pegsunercept [1] 46
108 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
109 TNF [27] Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D09944 Ozoralizumab [1] 46